JP2018531218A5 - - Google Patents

Download PDF

Info

Publication number
JP2018531218A5
JP2018531218A5 JP2018507641A JP2018507641A JP2018531218A5 JP 2018531218 A5 JP2018531218 A5 JP 2018531218A5 JP 2018507641 A JP2018507641 A JP 2018507641A JP 2018507641 A JP2018507641 A JP 2018507641A JP 2018531218 A5 JP2018531218 A5 JP 2018531218A5
Authority
JP
Japan
Prior art keywords
group
tautomer
pharmaceutically acceptable
acceptable salt
membered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018507641A
Other languages
English (en)
Japanese (ja)
Other versions
JP6898306B2 (ja
JP2018531218A (ja
JP2018531218A6 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2016/092989 external-priority patent/WO2017024968A1/zh
Publication of JP2018531218A publication Critical patent/JP2018531218A/ja
Publication of JP2018531218A6 publication Critical patent/JP2018531218A6/ja
Publication of JP2018531218A5 publication Critical patent/JP2018531218A5/ja
Application granted granted Critical
Publication of JP6898306B2 publication Critical patent/JP6898306B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018507641A 2015-08-07 2016-08-03 Fgfr及びvegfr阻害剤であるビニル化合物 Active JP6898306B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201510484124 2015-08-07
CN201510484124.6 2015-08-07
CN201510908082 2015-12-09
CN201510908082.4 2015-12-09
PCT/CN2016/092989 WO2017024968A1 (zh) 2015-08-07 2016-08-03 作为fgfr和vegfr抑制剂的乙烯基化合物

Publications (4)

Publication Number Publication Date
JP2018531218A JP2018531218A (ja) 2018-10-25
JP2018531218A6 JP2018531218A6 (ja) 2018-12-13
JP2018531218A5 true JP2018531218A5 (enExample) 2019-09-19
JP6898306B2 JP6898306B2 (ja) 2021-07-07

Family

ID=57983012

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018507641A Active JP6898306B2 (ja) 2015-08-07 2016-08-03 Fgfr及びvegfr阻害剤であるビニル化合物

Country Status (5)

Country Link
US (1) US10519133B2 (enExample)
EP (1) EP3333157B1 (enExample)
JP (1) JP6898306B2 (enExample)
CN (1) CN107922349B (enExample)
WO (1) WO2017024968A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6803410B2 (ja) * 2017-02-14 2020-12-23 富士フイルム株式会社 インダゾール化合物の製造方法およびインダゾール化合物
US11078194B2 (en) * 2017-12-07 2021-08-03 Harbin Zhenbao Pharmaceutical Co., Ltd. Salt form and crystal form serving as FGFR and VEGFR inhibitor compounds, and preparation method therefor
WO2020135878A1 (zh) * 2018-12-29 2020-07-02 南京明德新药研发有限公司 作为fgfr和vegfr双重抑制剂的咪唑并吡啶衍生物
MX2021009261A (es) * 2019-02-02 2021-11-12 Shanghai Fosun Pharmaceutical Ind Development Co Ltd Compuesto de fluorovinilbenzamida como inmunomodulador pd-l1.
KR102668124B1 (ko) * 2019-02-02 2024-05-23 노바온코 제이에스 테라퓨틱스 컴퍼니 리미티드 Pd-l1 면역조절제인 비닐 피리딘 카르복사미드 화합물
WO2020249096A1 (zh) * 2019-06-14 2020-12-17 南京明德新药研发有限公司 作为fgfr和vegfr双重抑制剂的并环类化合物
CN114072387B (zh) * 2019-11-06 2024-03-08 暨南大学 吲唑类化合物及其药用组合物和应用
WO2021138391A1 (en) * 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
CN113666911B (zh) * 2020-08-11 2025-08-26 河南迈英诺医药科技有限公司 Fgfr抑制剂化合物及其用途
JP2023553835A (ja) * 2020-12-17 2023-12-26 ブロッサムヒル・セラピューティクス・インコーポレイテッド 大環状化合物およびそれらの使用
MX2023007793A (es) * 2020-12-30 2023-09-22 Tyra Biosciences Inc Compuestos de indazol como inhibidores de cinasas.
CN116761798A (zh) * 2020-12-30 2023-09-15 泰拉生物科学公司 作为激酶抑制剂的吲唑类化合物
WO2023279041A1 (en) * 2021-06-30 2023-01-05 Tyra Biosciences, Inc. Indazole compounds
IL317558A (en) * 2022-06-29 2025-02-01 Tyra Biosciences Inc Indazole compounds
CN116239623B (zh) * 2022-11-18 2025-11-18 江西亚太科技发展有限公司 一种硼酸酯的制备方法及其应用
WO2024137742A1 (en) 2022-12-20 2024-06-27 Blueprint Medicines Corporation Compounds and compositions as fgfr3 degraders and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020010137A1 (en) * 1997-09-18 2002-01-24 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
YU54202A (sh) * 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
BRPI0113757B8 (pt) 2000-09-11 2017-11-07 Chiron Corp derivados de quinolinona como inibidores de tirosina quinase
JP2004536113A (ja) * 2001-07-03 2004-12-02 カイロン コーポレイション チロシンキナーゼおよびセリン/スレオニンキナーゼのインヒビターとしてのインダゾールベンズイミダゾール化合物
CN1656079A (zh) 2002-05-31 2005-08-17 卫材株式会社 吡唑化合物和含有该化合物的药物组合物
EP1582211A1 (en) 2002-12-03 2005-10-05 Kyowa Hakko Kogyo Co., Ltd. Jnk inhibitor
AU2003286321A1 (en) * 2002-12-19 2004-07-14 Pfizer Inc. 2-(1h-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophtalmic diseases
WO2007058626A1 (en) * 2005-11-16 2007-05-24 S*Bio Pte Ltd Indazole compounds
US8008481B2 (en) * 2006-03-31 2011-08-30 Ericsson Anna M Indazole compounds
JO2860B1 (en) * 2009-05-07 2015-03-15 ايلي ليلي اند كومباني Phenylendazolyl compounds

Similar Documents

Publication Publication Date Title
JP2019524883A5 (enExample)
JP2021523221A5 (enExample)
JP2020169171A5 (enExample)
JP2022525069A5 (enExample)
JP2006515858A5 (enExample)
JP2017504576A5 (enExample)
JP2016121196A5 (enExample)
JP2018528261A5 (enExample)
JP2021523225A5 (enExample)
JP2016515560A5 (enExample)
JP2014503525A5 (enExample)
JP2014503574A5 (enExample)
JP2020529994A5 (enExample)
JP2016130266A5 (enExample)
JP2008505157A5 (enExample)
JP2020063289A5 (enExample)
JP2019535723A5 (enExample)
JP2020128426A5 (enExample)
JP2020500869A5 (enExample)
JP2018529690A5 (enExample)
JP2017508733A5 (enExample)
JP2015511232A5 (enExample)
JP2022533939A5 (enExample)
JP2006509842A5 (enExample)
JP2017519796A5 (enExample)